LIVN vs GKOS

For growth investors, Glaukos Corporation (GKOS) is the stronger pick with 32.

3% revenue growth year-over-year, versus 10. 7% for LivaNova PLC (LIVN). Analysts rate LivaNova PLC (LIVN) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +74.

7%, compared to -13. 3% for LivaNova PLC (LIVN). Over 10 years, the gap is even starker: GKOS returned +454. 5% versus LIVN's +48. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Glaukos Corporation (GKOS) is the lower-risk stock at 1.

16β versus LivaNova PLC's 1. 33β — meaning LIVN is approximately 15% more volatile than GKOS relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 39% for LivaNova PLC — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Glaukos Corporation (GKOS) is pulling ahead at 32.

3% versus 10. 7% for LivaNova PLC (LIVN). On earnings-per-share growth, the picture is similar: Glaukos Corporation grew EPS -18. 4% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, GKOS leads at 21. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

LivaNova PLC (LIVN) is the more profitable company, earning -17.

5% net margin versus -37. 0% for Glaukos Corporation — meaning it keeps -17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIVN leads at 14. 4% versus -17. 1% for GKOS. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for LIVN: 10.

3% to $79. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Glaukos Corporation (GKOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

16), +454. 5% 10Y return). Both have compounded well over 10 years (GKOS: +454. 5%, LIVN: +48. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LIVN is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.